Table 2.
Clinical trials of CD47/SIRPα-targeted bispecific antibodies in hematological malignancies
| Name | Initial time of clinical studies | phase | Type of tumors | ClinicalTrials.gov Identifier | Outcome measures |
|---|---|---|---|---|---|
| TG-1801 (NI-1701) | 2021.4 | Phase IB | B-cell lymphoma or CLL | NCT04806035 | To determine the recommended phase II dose (RP2D), ORR |
| IMM0306 | 2021.8 | Phase I | R/R CD20-positive B-NHL | NCT04746131 | Maximum Tolerated Dose (MTD) of IMM0306 as measured by incidence of DLTs (Dose Limiting Toxicity) |
| IBI-322 | 2021.5 | Phase I | Hematological malignancies | NCT04795128 | treatment related AEs, ORR |
| IBI-322 | 2021.12 | Phase IA/IB | Myeloid Tumor | NCT05148442 | Treatment related AEs, ORR |
| DSP107 | 2021.9 | Phase IB/II | MDS, AML and T-cell lymphoproliferative disease | NCT04937166 | Treatment related AEs, Dose Limiting Toxicities (DLT), ORR, MRD |
| HX009 | 2021.12 | Phase I/II | R/R-lymphoma | NCT05189093 | Treatment related AEs, ORR, PFS, DOR, DCR, PK/PC |
| JMT601 (CPO107) | 2021.12 | Phase I/II | Advanced CD20-positive NHL | NCT04853329 | To determine the recommended single-agent CPO107 RP2D, safety, efficacy |
| SG2501 | 2022.4 | Phase IA/IB | R/R hematological malignancies and lymphoma | NCT05293912 | To evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy |